{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:57:46Z","timestamp":1776484666122,"version":"3.51.2"},"reference-count":51,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fayez Sarofim Lymphoma Program at Texas Children\u2019s Cancer Center","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"St. Baldrick\u2019s Innovation Award (C.E.A.)","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"SPORE in Lymphoma (C.E.A.)","award":["Heslop, CA126752"],"award-info":[{"award-number":["Heslop, CA126752"]}]},{"name":"St. Baldrick\u2019s International Scholar Award (N.W.O.)","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Pediatric Oncology Clinical Research Training Program, K12 (J.E.A.)","award":["CA090433"],"award-info":[{"award-number":["CA090433"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hodgkin lymphoma (HL) histopathology is characterized by rare malignant Reed\u2013Sternberg cells among an inflammatory infiltrate. We hypothesized that characteristics of inflammation in pediatric HL lesions would be reflected by the levels of inflammatory cytokines or chemokines in pre-therapy plasma of children with HL. The study objectives were to better define the inflammatory pre-therapy plasma proteome and identify plasma biomarkers associated with extent of disease and clinical outcomes in pediatric HL. Pre-therapy plasma samples were obtained from pediatric subjects with newly diagnosed HL and healthy pediatric controls. Plasma concentrations of 135 cytokines\/chemokines were measured with the Luminex platform. Associations between protein concentration and disease characteristics were determined using multivariate permutation tests with false discovery control. Fifty-six subjects with HL (mean age: 13 years, range 3\u201318) and 47 controls were analyzed. The cytokine\/chemokine profiles of subjects with HL were distinct from controls, and unique cytokines\/chemokines were associated with high-risk disease (IL-10, TNF-\u03b1, IFN-\u03b3, IL-8) and slow early response (CCL13, IFN-\u03bb1, IL-8). TNFSF10 was significantly elevated among those who ultimately relapsed and was significantly associated with worse event-free survival. These biomarkers could be incorporated into biologically based risk stratification to optimize outcomes and minimize toxicities in pediatric HL.<\/jats:p>","DOI":"10.3390\/cancers12123603","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T07:49:54Z","timestamp":1606895394000},"page":"3603","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-863X","authenticated-orcid":false,"given":"Jennifer E.","family":"Agrusa","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooks P.","family":"Scull","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshal A.","family":"Abhyankar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-904X","authenticated-orcid":false,"given":"Howard","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nmazuo W.","family":"Ozuah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikhia","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olive S.","family":"Eckstein","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9243-9544","authenticated-orcid":false,"given":"Nitya","family":"Gulati","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmoataz Abdel","family":"Fattah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader K.","family":"El-Mallawany","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayne H.","family":"Rouce","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZoAnn E.","family":"Dreyer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julienne","family":"Brackett","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith F.","family":"Margolin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Lubega","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terzah M.","family":"Horton","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Health System and The George Washington University, Washington, DC 20010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Monica","family":"Gramatges","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kala Y.","family":"Kamdar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth L.","family":"McClain","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsz-Kwong","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl E.","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer and Hematology Centers, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Poppema, S. (2005). Immunobiology and pathophysiology of Hodgkin lymphomas. Hematol. Am. Soc. Hematol. Educ. Program, 231\u2013238.","DOI":"10.1182\/asheducation-2005.1.231"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma","volume":"19","author":"Jones","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1182\/blood-2010-12-327346","article-title":"Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed\/refractory disease in classical Hodgkin lymphoma","volume":"117","author":"Kamper","year":"2011","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-13-1879","article-title":"Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma","volume":"19","author":"Marri","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bjh.14317","article-title":"Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: Comparison of sGalectin-1, sCD163 and sCD30 with TARC","volume":"175","author":"Plattel","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.23361","article-title":"Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma","volume":"88","author":"Sauer","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjh.12759","article-title":"Current status of prognostication in classical Hodgkin lymphoma","volume":"165","author":"Venkataraman","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000117798","article-title":"Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma","volume":"17","author":"Abdelrazik","year":"2008","journal-title":"Med. Princ. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/08880010601052381","article-title":"Serum VEGF as a significant marker of treatment response in hodgkin lymphoma","volume":"24","author":"Maurice","year":"2007","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/pbc.22179","article-title":"Prognostic value of proangiogenic cytokines in children with lymphomas","volume":"53","author":"Sobol","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/088800199277470","article-title":"Serum levels and differential expression of intercellular adhesion molecule-1 in childhood leukemia and malignant lymphoma: Prognostic importance and relationship with survival","volume":"16","author":"Tacyildiz","year":"1999","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"67551","DOI":"10.18632\/oncotarget.11509","article-title":"Pediatric Hodgkin lymphoma: Biomarkers, drugs, and clinical trials for translational science and medicine","volume":"7","author":"Nagpal","year":"2016","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: A report from the Children\u2018s Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2010.08455.x","article-title":"Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents","volume":"152","author":"Daw","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/jnci\/djw249","article-title":"Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations","volume":"109","author":"Diefenbach","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2141.2007.06964.x","article-title":"Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22","volume":"140","author":"Niens","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3324\/haematol.2011.053199","article-title":"Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin\u2018s lymphoma","volume":"97","author":"Plattel","year":"2012","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cam4.585","article-title":"CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma","volume":"5","author":"Cuccaro","year":"2016","journal-title":"Cancer Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1756-8722-6-62","article-title":"Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+\/CD30+ cells in poor outcome Hodgkin lymphoma patients","volume":"6","author":"Gharbaran","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1080\/10428190802441339","article-title":"Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma","volume":"49","author":"Rautert","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_23","first-page":"1242","article-title":"Serum interleukin-2 receptor levels in Hodgkin disease and other solid tumors of childhood","volume":"7","author":"Pui","year":"1993","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5858\/2010-0060-OA.1","article-title":"Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma","volume":"135","author":"Gaiolla","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2014-07-537480","article-title":"Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma","volume":"125","author":"Connors","year":"2015","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.clinbiochem.2009.04.004","article-title":"Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin\u2018s lymphomas and acute lymphoblastic leukemias","volume":"42","author":"Bien","year":"2009","journal-title":"Clin. Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s12032-011-0010-1","article-title":"Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma","volume":"29","author":"Kowalska","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children\u2018s Oncology Group","volume":"34","author":"Appel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_29","first-page":"82","article-title":"A randomized Phase III trial of Brentuximab vedotin (Bv) for de novo High-Risk Classical Hodgkin Lymphoma (cHL) in children and adolescents-Study Design and Incorporation of secondary endoints in Children\u2019s Oncology Gorup (COG) AHOD1331","volume":"232","author":"Castellino","year":"2020","journal-title":"Klin. Padiatr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16014","article-title":"Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): A report from the Children\u2019s Oncology Group","volume":"187","author":"Kelly","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1023\/A:1026551727795","article-title":"Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin\u2019s disease","volume":"11","author":"Axdorph","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2006.08.1331","article-title":"Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin\u2019s lymphoma: A study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"25","author":"Casasnovas","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI114265","article-title":"Neutrophil-activating peptide-1\/interleukin 8, a novel cytokine that activates neutrophils","volume":"84","author":"Baggiolini","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_35","first-page":"1229","article-title":"Interleukin-8 in Hodgkin\u2019s disease. Preferential expression by reactive cells and association with neutrophil density","volume":"148","author":"Foss","year":"1996","journal-title":"Am. J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3109\/10428194.2014.963081","article-title":"CD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma","volume":"56","author":"Agur","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3109\/10428194.2013.824079","article-title":"CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma","volume":"55","author":"Kayal","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.2010.033316","article-title":"Macrophages predict treatment outcome in Hodgkin\u2019s lymphoma","volume":"96","author":"Steidl","year":"2011","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin-10 receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: An overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/1043-4666(90)90033-P","article-title":"Immunoenzymatic assessment of interferon-gamma in Hodgkin and Sternberg-Reed cells","volume":"2","author":"Gerdes","year":"1990","journal-title":"Cytokine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1080\/10428194.2017.1289520","article-title":"Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-\u03b3 expression in the neoplastic cells and macrophages of Hodgkin lymphoma: Clinicopathologic correlations and potential prognostic implications","volume":"58","author":"Vassilakopoulos","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1758834017749748","DOI":"10.1177\/1758834017749748","article-title":"Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients","volume":"10","author":"Karachaliou","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10555-006-9005-3","article-title":"TNF-alpha in promotion and progression of cancer","volume":"25","author":"Balkwill","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"R228","DOI":"10.1186\/ar4067","article-title":"Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis","volume":"14","author":"Wang","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.V94.6.1899","article-title":"CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist","volume":"94","author":"Blanpain","year":"1999","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/annonc\/13.S1.52","article-title":"Chemokines, cytokines and their receptors in Hodgkin\u2019s lymphoma cell lines and tissues","volume":"13","author":"Maggio","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1128\/MCB.00692-15","article-title":"RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-kappaB Activation and Lymphoma Survival","volume":"35","author":"Zhang","year":"2015","journal-title":"Mol. Cell. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V97.9.2798","article-title":"Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin\/Reed-Sternberg cells","volume":"97","author":"Hinz","year":"2001","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.19.00812","article-title":"Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children\u2019s Oncology Group Study","volume":"37","author":"Kahn","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3603\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:40:36Z","timestamp":1760179236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["cancers12123603"],"URL":"https:\/\/doi.org\/10.3390\/cancers12123603","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,2]]}}}